Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre

Irish Journal of Medical Science

Volumn 182, Issue 4, 2013, Pages 693-695

  O'Connor A ^a   Taneike, I ^a   Nami, A ^a   Fitzgerald, N ^a   Ryan, B ^a   Breslin, N ^a   O'Connor H ^a   McNamara, D ^a   Murphy, P ^a   O'Morain C ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Compliance; Helicobacter pylori; Levofloxacin; Resistance; Rifabutin; Tetracycline

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; RIFABUTIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; COHORT ANALYSIS; ENDOSCOPY; EPSILOMETER TEST; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; STOMACH BIOPSY; AGE; BIOPSY; DRUG EFFECT; IRELAND; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; STOMACH; TREATMENT OUTCOME;

AGE FACTORS; ANTI-BACTERIAL AGENTS; BIOPSY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IRELAND; LEVOFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RIFABUTIN; STOMACH; TETRACYCLINE; TREATMENT OUTCOME;

EID: 85027923696     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-013-0957-3     Document Type: Article

References (25)

1. Lind T, Veldhuyzen van Zanten S, Unge P et al (1996) Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter 1:138–144
2. Malfertheiner P, Megraud F, O’Morain C et al (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 56:772–781
3. Chey WD, Wong BC (2007) American college of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102:1808–1825
4. Saad RJ, Chey WD (2006) Treatment of Helicobacter pylori infection in 2006. Gastroenterol Hepatol Annu Rev 1:30–35
5. Kadayifci A, Buyukhatipoglu H, Cemil Savas M et al (2006) Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 28:1960–1966
6. Fuccio L, Zagari RM, Eusebi LH et al (2009) Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 151(2):121–128
7. Essa AS, Kramer JR, Graham DY et al (2009) Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing ‘‘concomitant therapy’’ versus triple therapy for Helicobacter pylori eradication. Helicobacter 14(2):109–118
8. Chisholm SA, Teare EL, Davies K et al (2007) Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000–2005). Euro Surveill 12(7):E3–E4
9. Raymond J, Lamarque D, Kalach N et al (2010) High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 15(1):21–27
10. O’Connor A, Taneike I, Nami A et al (2010) Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. Eur J Gastroenterol Hepatol 22(9):1123–1127
11. Gisbert JP, Bermejo F, Castro-Fernández M et al (2008) Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 103(1):71–76
12. Hung KH, Sheu BS, Chang WL et al (2009) Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a university hospital in southern Taiwan. Helicobacter 14(1):61–65
13. Van der Poorten D, Katelaris PH (2007) The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 26(11–12):1537–1542
14. Hojo M, Miwa H, Nagahara A et al (2001) Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 36:690–700
15. Gisbert JP, Boixeda D, Bermejo F et al (1999) Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 11(9):1049–1054
16. Clinical and Laboratory Standards Institute (2007) Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement: CLSI document M100-S17 [ISBN 1-56238-625-5]. Clinical and Laboratory Standards Institute, USA
17. Chisholm SA, Owen RJ (2009) Frequency and molecular characteristics of ciprofloxacin and rifampicin resistant Helicobacter pylori from gastric infections in the UK. J Med Microbiol 58:1322–1328
18. De Francesco V, Giorgio F, Hassan C et al (2010) Worldwide H. pylori antibiotic resistance: a systematic review. J Gastroint-estin Liver Dis 19(4):409–414
19. Glocker E, Stueger HP, Kist M (2007) Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 51:346–349
20. Adriaenssens N, Coenen S, Versporten A et al (2011) European surveillance of antimicrobial consumption (ESAC): outpatient antibiotic use in Europe (1997–2009). J Antimicrob Chemother 66(s6):vi3–vi12
21. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M et al (2010) Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 31(10):1077–1084
22. Malfertheiner P, Bazzoli F, Delchier JC et al (2011) Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 377(9769): 905–913
23. Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF et al (2012) Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother 67(1):170–173
24. Coelho LG, Moretzsohn LD, Vieira WL et al (2005) New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment Pharmacol Ther 21:783–787
25. Gisbert JP, Calvet X (2012) Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 35(2):209–221